Spero Therapeutics SPRO is preparing to release its quarterly earnings on Thursday, 2024-11-14. Here's a brief overview of ...

Spero Therapeutics Inc (NASDAQ:SPRO) is set to release its Q3 2024 earnings on Nov 14, 2024. The consensus estimate for Q3 ...

The company has also laid off 39% of its staff as it discontinued the development of SPR720 for non-tuberculous mycobacterial ...

Following disappointing results for an antibiotic candidate whose development program is now being suspended, Spero ...

On Wednesday, Spero Therapeutics Inc (SPRO) stock saw a decline, ending the day at $1.29 which represents a decrease of $-0.02 or -1.53% from the prior close of $1.31. The stock opened at $1.04 and ...

Oct. 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare ...

Stock analysts at HC Wainwright raised their Q3 2024 earnings per share (EPS) estimates for shares of Spero Therapeutics in a ...

Spero Therapeutics (SPRO) announced that a planned interim analysis of the Phase 2a proof-of-concept study of SPR720 for the treatment of ...

This is the second time in recent years that uncertainty about a drug's future has led to layoffs at Spero Therapeutics. Spero Therapeutics Inc. is pulling the plug on a lung disease drug trial ...

马萨诸塞州剑桥 - Spero Therapeutics, Inc. (NASDAQ:SPRO)宣布暂停其SPR720开发项目，此前一项中期分析显示，该药物在非结核分枝杆菌肺病 (NTM-PD)治疗的2a期概念验证研究中未能达到主要终点。这项包含16名患者数据的分析显示，与安慰剂相比差异不足，并存在潜在的剂量限制性安全问题，包括可逆的3级肝毒性病例。

周一，H.C. Wainwright调整了对Spero Therapeutics (NASDAQ:SPRO)的展望，将目标价从之前的$7下调至$5，同时维持对该股的买入评级。这一修订是在Spero Therapeutics上周宣布其SPR720治疗非结核分枝杆菌肺病 (NTM-PD)的二期a概念验证研究的中期结果之后做出的。

Spero Therapeutics has suspended the development of its antibiotic SPR720, after the therapy failed to meet the primary endpoint in a Phase IIa trial in patients with non-tuberculous mycobacterial ...